Making this vaccine is simple. Once we have the cobalt liposomes and the Pfs25-histidine molecules, we simply mix these parts together, and the structures form spontaneously. When this Pfs25 liposome is injected into mice, it triggers high quantities of antibodies. The antibodies in the mice blocked development of parasites in the gut of the mosquito. So we expect that when an uninfected mosquito bites a person infected with the malaria parasite, the blood it sucks up will carry the parasite and the human antibodies that will prevent the parasite from multiplying in the insect’s gut. When we tested this vaccine in mice, the animals continued to produce antibodies for more than 250 days. These antibodies produced throughout this period prevented the development of the malaria parasite throughout this period.
News 
Market Data 
Discover 
